New drug tested to fight hardening skin and lung damage in severe scleroderma
NCT ID NCT04440592
Summary
This study tested an investigational drug called MT-7117 to see if it could improve the condition of people with diffuse cutaneous systemic sclerosis, a severe form of scleroderma. For one year, 76 participants with active, early-stage disease received either the drug or a placebo. Researchers measured changes in skin thickness, lung function, and overall disability to see if the treatment was effective.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Arizona Arthritis
Glendale, Arizona, 85306, United States
-
CIRI, Centrum fur innovative Diagnostik und Therapie Rheumatologie und Immunologie (GmbH) Am Klinikum der Johann Wolfgang Goethe-Universitat
Frankfurt am Main, Hesse, 60590, Germany
-
Centre Hospitalier Universitaire (CHU) de Liege - Domaine Universitaire du Sart Tilman
Liège, 4000, Belgium
-
Centrum Kliniczno-Badawcze J.Brzezicki, B.Gornikiewicz-Brzezicka Lekarze Spolka partnerska
Elblag, 82-300, Poland
-
Centrum Medyczne Oporow
Wroclaw, 52-416, Poland
-
Centrum Medyczne Plejady
Krakow, 30-363, Poland
-
GNP Research
Hollywood, Florida, 33024, United States
-
Hospital Del Mar
Barcelona, 08003, Spain
-
Hospital Regional Universitario de Málaga
Málaga, 29009, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital de la Santa Creu i Sant Pau
Barcelona, 08041, Spain
-
Institut d'Investigacio i Innovacio Parc Tauli, Hospital Universitari Parc Taulí
Sabadell, Barcelona, 08208, Spain
-
Internistisches Zentrum des Universitaetsklinikums Erlangen
Erlangen, 91054, Germany
-
Johns Hopkins University
Baltimore, Maryland, 21218, United States
-
Malopolskie Centrum Kliniczne
Krakow, 30-149, Poland
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Medycyna Kliniczna
Warsaw, 00-874, Poland
-
Medyczne Centrum Hetmanska
Poznan, 60-218, Poland
-
Millennium Research
Ormond Beach, Florida, 32174, United States
-
Mount Sinai Hospital, The Rebecca Macdonald Centre For Arthritis And Autoimmune Disease
Toronto, Ontario, M5T 3L9, Canada
-
Pacific Arthritis Care Center
Los Angeles, California, 90045, United States
-
Shelby Research, LLC
Memphis, Tennessee, 38119, United States
-
The Board of Trustees of the Leland Stanford Junior University
Redwood City, California, 94063, United States
-
The Royal Free Hospital - Royal Free London NHS Foundation Trust
London, NW3 2QG, United Kingdom
-
The University of Texas Medical School at Houston
Houston, Texas, 77030, United States
-
UZ Leuven
Leuven, Vlaam Gewest, 3000, Belgium
-
Universita degli Studi di Milano - Azienda Ospedaliera Istituto Ortopedico Gaetano Pini
Milan, Lombardy, 20122, Italy
-
Universitair Ziekenhuis Gent
Ghent, 9000, Belgium
-
University Hospital Of Tuebingen
Tübingen, Baden-Wuettemberg, 72076, Germany
-
University of Ferrara Azienda Ospedaliero-Universitaria Sant' Anna
Cona, Ferrera, 44124, Italy
-
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109-5422, United States
-
Uniwersytecki Szpital Kliniczny w Bialymstoku
Bialystok, 15-276, Poland
-
Western General Hospital
Edinburgh, EH4 2XU, United Kingdom
-
Yale School of Medicine - The Anlyan Center (TAC) for Medical Research & Education
New Haven, Connecticut, 06519, United States
Conditions
Explore the condition pages connected to this study.